I. Agodoa

发表

Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States.

L. Spangler, C. O’Malley, A. Singer, 2015, Mayo Clinic proceedings.

Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.

S. Silverman, E. Orwoll, I. Agodoa, 2014, Bone.

Analysis of osteoporosis treatment patterns with bisphosphonates and outcomes among postmenopausal veterans.

Olga V. Patterson, S. Duvall, R. Nelson, 2015, Bone.

A Review of the Costs and Cost Effectiveness of Interventions in Chronic Kidney Disease

J. Menzin, D. Weiner, P. Neumann, 2011, PharmacoEconomics.

Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trial

D. Churchill, T. Mayne, P. Keown, 2010, Hemodialysis international. International Symposium on Home Hemodialysis.

Interaction between Na+/phosphate-cotransporter and the adrenoceptors in myocardial depression.

A. Ofori, I. Agodoa, M. Onwochei, 1998, Journal of cardiovascular pharmacology.

What drives transcranial Doppler velocity improvement in paediatric sickle cell anaemia: analysis from the Sickle Cell Clinical Research and Intervention Program (SCCRIP) longitudinal cohort study

Winfred C. Wang, I. Agodoa, G. Kang, 2021, British journal of haematology.

Opioid utilization patterns in United States individuals with sickle cell disease

I. Agodoa, S. Ballas, S. Wade, 2018, American journal of hematology.

Efficacy and Safety of Voxelotor in Adolescents and Adults with Sickle Cell Disease: HOPE Trial 72-Week Analysis

K. Ataga, E. Vichinsky, I. Agodoa, 2020 .

Real-world effectiveness of voxelotor for treating sickle cell disease in the US: a large claims data analysis

T. Delea, I. Agodoa, O. Alvarez, 2022, Expert review of hematology.

Impact of voxelotor (GBT440) on unconjugated bilirubin and jaundice in sickle cell disease

L. Burke, K. Fox, I. Agodoa, 2018, Hematology reports.

Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease

D. Lubeck, N. Bhakta, I. Agodoa, 2019, JAMA network open.

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.

K. Ataga, E. Vichinsky, I. Agodoa, 2021, The Lancet. Haematology.

Low hemoglobin increases risk for cerebrovascular disease, kidney disease, pulmonary vasculopathy, and mortality in sickle cell disease: A systematic literature review and meta-analysis

K. Ataga, V. Gordeuk, K. Gittings, 2020, PloS one.

The inpatient experience and predictors of length of stay for patients hospitalized with systolic heart failure: comparison by commercial, Medicaid, and Medicare payer type

David M. Smith, L. Allen, I. Agodoa, 2013, Journal of medical economics.

Rates and predictors of 30-day readmission among commercially insured and Medicaid-enrolled patients hospitalized with systolic heart failure.

David M. Smith, L. Allen, K. Tomic, 2012, Circulation. Heart failure.

Hemoglobin and End-Organ Damage in Individuals with Sickle Cell Disease

T. Delea, I. Agodoa, W. Ershler, 2023, Current Therapeutic Research.

Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients.

D. Revicki, K. Johansen, I. Agodoa, 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study

I. Agodoa, S. Lanzkron, H. Varker, 2020, Journal of managed care & specialty pharmacy.

Economic Burden of End Organ Damage Among Patients with Sickle Cell Disease in the US

I. Agodoa, S. Lanzkron, H. Varker, 2019, Blood.

Patient-Reported Outcomes in Chronic Heart Failure: Applicability for Regulatory Approval.

J. Spertus, D. Patrick, I. Wiklund, 2016, JACC. Heart failure.

Association of anemia correction with health related quality of life in patients not on dialysis*

D. Globe, R. Kewalramani, I. Agodoa, 2007, Current medical research and opinion.

A Systematic Review of Osteoporosis Medication Adherence and Osteoporosis-Related Fracture Costs in Men

Y. Mikyas, N. Yurgin, I. Agodoa, 2014, Applied Health Economics and Health Policy.

Association between bisphosphonate switching behavior and cost outcomes in postmenopausal United States veterans

S. Duvall, R. Adler, J. LaFleur, 2013 .

Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.

Jacques P. Brown, I. Agodoa, J. V. D. van den Bergh, 2015, The Journal of clinical endocrinology and metabolism.

Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective

S. Silverman, E. Orwoll, I. Agodoa, 2015, Journal of osteoporosis.

Patient-Reported Experiences in Voxelotor-Treated Children and Adults with Sickle Cell Disease: A Semistructured Interview Study

I. Agodoa, Wally R. Smith, Clark Brown, 2023, BioMed Research International.

Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient.

M. Perales, S. Devine, R. Maziarz, 2023, Transplantation and cellular therapy.

Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.

Jacques P. Brown, I. Agodoa, J. V. D. van den Bergh, 2015, The Journal of clinical endocrinology and metabolism.

GBT021601, a Next Generation HbS Polymerization Inhibitor: Results of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Adults Living with Sickle Cell Disease and Healthy Volunteers

A. Redfern, E. Lisbon, I. Agodoa, 2021, Blood.

Higher Hemoglobin Levels Achieved with Voxelotor Are Associated with Lower Vaso-occlusive Crisis Incidence: 72-Week Analysis from the HOPE Study

K. Ataga, E. Vichinsky, V. Gordeuk, 2020 .